Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: The Company develops noninvasive diagnostics for early-stage lung cancer (CyPath® Lung) using flow cytometry and AI. It operates through two segments: Diagnostic R&D and Laboratory Services (via subsidiary Precision Pathology Laboratory Services, LLC). The Company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Sept 30, 2025 Balance Sheet |
|---|---|---|---|
| Net Revenue | $1,446,066 | $4,569,146 | - |
| Net Loss | $(5,051,084) | $(11,772,288) | - |
| Loss Per Share (Basic/Diluted) | $(4.74) | $(7.55) | - |
| Cash and Cash Equivalents | - | - | $7,669,195 |
| Total Assets | - | - | $11,546,369 |
| Total Liabilities | - | - | $2,644,171 |
| Stockholders' Equity | - | - | $8,902,198 |
| Accumulated Deficit | - | - | $(65,416,598) |
Cash Flow (Nine Months Ended Sept 30, 2025):
- Net cash used in operating activities: $(6,769,279)
- Net cash used in investing activities: $(60,567)
- Net cash provided by financing activities: $13,393,750
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenue decreased 36% year-over-year (YoY) for the nine months ended Sept 30, 2025 ($4.6M vs. $7.2M). This was driven by the strategic discontinuation of unprofitable pathology services.
- CyPath® Lung Growth: Despite the overall revenue decline, CyPath® Lung testing revenue increased 86% YoY to $619,000 for the nine months, with test volume rising to 775 (from 393 in the prior year).
- Operating Expenses: Total operating expenses decreased 9% YoY to $12.0M. Direct costs dropped 25% due to operational streamlining. However, clinical development expenses surged 112% to $411K due to professional fees for pivotal trial strategy.
- Net Loss Expansion: Net loss increased to $11.8M for the nine months (vs. $6.1M prior year). This was significantly impacted by a $3.8M non-cash loss from the change in fair value of warrants issued, which were subsequently reclassified to equity.
- Liquidity Improvement: Cash balances increased from $1.1M at year-end 2024 to $7.7M at Sept 30, 2025, following $13.4M in gross proceeds from equity transactions in Q3 2025.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months. Current cash resources are projected to support operations only through May 2026.
- Capital Needs: The Company must raise additional capital through equity, debt, or strategic relationships to fund operations and development. Failure to do so may result in curtailment of operations.
- Nasdaq Compliance: The Company recently regained compliance with Nasdaq Minimum Bid Price and Minimum Stockholders' Equity rules following an appeal. It is now subject to a mandatory one-year panel monitor; failure to maintain compliance could result in delisting.
- Outlook: Management anticipates continued losses. Growth is focused on expanding CyPath® Lung sales (notably with Veterans' hospitals) and advancing diagnostic tests for COPD and asthma.
- Unusual Items: The financial results include significant non-cash charges related to warrant liability remeasurement ($3.8M for the nine months) and offering costs ($1.4M).
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "May 2026" operational runway estimate given the high burn rate and reliance on future financing.
- Revenue Mix: Confirm the sustainability of the revenue shift from general pathology services to CyPath® Lung testing and the associated gross margins.
- Warrant Liability: Review the accounting treatment of the warrant liability reclassification to equity and ensure no further remeasurement charges are expected.
- Nasdaq Status: Monitor the one-year compliance monitoring period to ensure the stock remains listed on Nasdaq.
- Financing Terms: Assess the dilution impact of recent and potential future equity offerings, including the Series B Convertible Preferred Stock and ATM program.